Intellia Therapeutics (NTLA) vs Alpha Teknova (TKNO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Alpha Teknova (TKNO) has outperformed Intellia Therapeutics (NTLA) over the past year, gaining 66.2% versus a loss of 42.7%. Over five years, TKNO leads with a -62.3% price change compared with -91.0% for NTLA. Intellia Therapeutics is the larger company by market cap ($1.64 billion vs $467.6 million), about 3.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NTLA | TKNO |
|---|---|---|
| Share price | $11.71 | $8.71 |
| Market cap | $1.64B | $467.62M |
| 1-day change | -5.34% | -0.46% |
| YTD return | +30.26% | +129.21% |
| 1-year return | -42.71% | +66.22% |
| 5-year return | -91.03% | -62.29% |
| EPS (TTM) | $-3.35 | $-0.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.25 | $9.48 |
| 52-week low | $7.95 | $1.91 |
| Distance from 52-week high | -58.55% | -8.12% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +97.35% | +3.33% |
| Average volume | 4.16M | 230.99K |
| Shares outstanding | 140.13M | 53.69M |
| Employees | 377 | 158 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Intellia Therapeutics is about 3.5 times larger than Alpha Teknova by market value ($1.64B vs $467.62M).
- TKNO has outperformed NTLA by 108.9 percentage points over the past year.
About Intellia Therapeutics
NTLA stock →Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 377 employees
About Alpha Teknova
TKNO stock →Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 158 employees
NTLA vs TKNO FAQ
Which is bigger, Intellia Therapeutics or Alpha Teknova?
Intellia Therapeutics (NTLA) is larger, with a market capitalization of $1.64B compared with $467.62M for Alpha Teknova (TKNO).
Which stock has performed better over the past year, NTLA or TKNO?
TKNO returned +66.22% over the past 12 months, compared with -42.71% for NTLA (price return, excluding dividends). Past performance does not predict future results.
Are Intellia Therapeutics and Alpha Teknova in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.